A 2-year multicenter, observational study oevaluating T and B lymphocytopenia in patients treated with Ocrelizumab switching from other treatments compared to naive
Latest Information Update: 04 Nov 2020
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 04 Nov 2020 New trial record
- 13 Sep 2020 Results presented at the 8th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis